Stem definition | Drug id | CAS RN |
---|---|---|
prednisone and prednisolone derivatives | 4451 | 125-02-0 |
None
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 82 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 19, 1973 | FDA | NOVARTIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bedridden | 89.44 | 37.50 | 26 | 1569 | 9133 | 46675334 |
Lower limb fracture | 81.68 | 37.50 | 26 | 1569 | 12372 | 46672095 |
Foot fracture | 70.03 | 37.50 | 26 | 1569 | 19556 | 46664911 |
Osteoporosis | 63.86 | 37.50 | 30 | 1565 | 40578 | 46643889 |
Enterococcal sepsis | 54.92 | 37.50 | 12 | 1583 | 1328 | 46683139 |
Hepatitis B reactivation | 48.05 | 37.50 | 11 | 1584 | 1503 | 46682964 |
Meningitis cryptococcal | 45.08 | 37.50 | 10 | 1585 | 1185 | 46683282 |
Mobility decreased | 44.61 | 37.50 | 27 | 1568 | 60567 | 46623900 |
Loss of personal independence in daily activities | 43.44 | 37.50 | 26 | 1569 | 57157 | 46627310 |
General physical health deterioration | 43.39 | 37.50 | 34 | 1561 | 115735 | 46568732 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Choroiditis | 155.51 | 33.50 | 27 | 1111 | 808 | 29950532 |
Endophthalmitis | 133.26 | 33.50 | 30 | 1108 | 3450 | 29947890 |
Intraocular pressure increased | 126.82 | 33.50 | 31 | 1107 | 5089 | 29946251 |
Uveitis | 109.81 | 33.50 | 28 | 1110 | 5449 | 29945891 |
Visual acuity reduced | 92.20 | 33.50 | 31 | 1107 | 15815 | 29935525 |
Eye pain | 88.58 | 33.50 | 28 | 1110 | 11761 | 29939579 |
Condition aggravated | 45.04 | 33.50 | 39 | 1099 | 137827 | 29813513 |
Hepatitis B reactivation | 39.89 | 33.50 | 11 | 1127 | 2866 | 29948474 |
Meningomyelitis herpes | 35.76 | 33.50 | 5 | 1133 | 33 | 29951307 |
Source | Code | Description |
---|---|---|
CHEBI has role | CHEBI:50266 | prodrugs |
CHEBI has role | CHEBI:50857 | anti-allergic agents |
CHEBI has role | CHEBI:63562 | glucocorticoid receptor agonists |
CHEBI has role | CHEBI:66981 | ophthalmologicals |
CHEBI has role | CHEBI:67079 | antiinflammatory agents |
MeSH PA | D005938 | Glucocorticoids |
MeSH PA | D006728 | Hormones |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Blepharoconjunctivitis | indication | 68659002 | DOID:2456 |
Iridocyclitis | indication | 77971008 | |
Bacterial conjunctivitis | indication | 128350005 | DOID:9700 |
Uveitis | indication | 128473001 | DOID:13141 |
Infective blepharitis | indication | 312219000 | |
Superficial Ocular Infection | indication | ||
Ocular hypertension | contraindication | 4210003 | DOID:9282 |
Herpes simplex keratitis | contraindication | 9389005 | |
Herpes simplex dendritic keratitis | contraindication | 29943008 | |
Fungal infection of eye | contraindication | 31194008 | |
Severe myopia | contraindication | 34187009 | |
Tuberculosis of eye | contraindication | 49107007 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
Krukenberg spindle | contraindication | 85430004 | |
Anemia due to enzyme deficiency | contraindication | 111577008 | |
Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
Eye infection | contraindication | 128351009 | |
Bacterial infection of eye | contraindication | 128984004 | |
Viral eye infection | contraindication | 312132001 | |
Vaccinia keratitis | contraindication | 397552005 | |
Porphyria | contraindication | 418470004 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 1.75 | acidic |
pKa2 | 6.8 | acidic |
pKa3 | 12.78 | acidic |
pKa4 | 13.76 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glucocorticoid receptor | Nuclear hormone receptor | AGONIST | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
D00981 | KEGG_DRUG |
4017987 | VUID |
N0000146333 | NUI |
4017987 | VANDF |
C0138273 | UMLSCUI |
CHEBI:8379 | CHEBI |
CHEMBL1201231 | ChEMBL_ID |
CHEMBL1201014 | ChEMBL_ID |
C009022 | MESH_SUPPLEMENTAL_RECORD_UI |
IV021NXA9J | UNII |
72078 | PUBCHEM_CID |
DB14631 | DRUGBANK_ID |
55062 | RXNORM |
16516 | MMSL |
44390 | MMSL |
5349 | MMSL |
002157 | NDDF |
96335004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0759 | SOLUTION | 15 mg | ORAL | ANDA | 20 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0773 | SOLUTION | 10 mg | ORAL | ANDA | 20 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0777 | SOLUTION | 20 mg | ORAL | ANDA | 20 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0902 | SOLUTION | 5 mg | ORAL | ANDA | 17 sections |
Prednisolone Sodium Phosphate Oral Solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0178-0582 | SOLUTION | 25 mg | ORAL | ANDA | 16 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 11695-1431 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 14 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13925-166 | SOLUTION | 5 mg | ORAL | NDA | 17 sections |
PREDNISOLONE SODIUM PHOSPHATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13985-025 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 14 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0759 | SOLUTION | 15 mg | ORAL | ANDA | 19 sections |
Sulfacetamide Sodium and Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-186 | SOLUTION | 2.50 mg | OPHTHALMIC | ANDA | 18 sections |
Sulfacetamide Sodium and Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 24208-317 | SOLUTION/ DROPS | 2.30 mg | OPHTHALMIC | ANDA | 20 sections |
PREDNISOLONE SODIUM PHOSPHATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-715 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 14 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-102 | SOLUTION | 15 mg | ORAL | ANDA | 11 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42799-812 | SOLUTION | 10 mg | ORAL | ANDA | 20 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42799-813 | SOLUTION | 20 mg | ORAL | ANDA | 20 sections |
Prednisolone Sodium Phosphate Oral Solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44523-182 | SOLUTION | 25 mg | ORAL | ANDA | 16 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0955 | SOLUTION | 15 mg | ORAL | ANDA | 10 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-1582 | SOLUTION | 15 mg | ORAL | ANDA | 19 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-040 | SOLUTION | 5 mg | ORAL | ANDA | 19 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50436-0759 | SOLUTION | 15 mg | ORAL | ANDA | 19 sections |
Sulfacetamide Sodium and Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53002-8690 | SOLUTION/ DROPS | 2.30 mg | OPHTHALMIC | ANDA | 19 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5242 | SOLUTION | 15 mg | ORAL | ANDA | 11 sections |
OrapredODT | Human Prescription Drug Label | 1 | 59212-700 | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | NDA | 25 sections |
OrapredODT | Human Prescription Drug Label | 1 | 59212-701 | TABLET, ORALLY DISINTEGRATING | 15 mg | ORAL | NDA | 25 sections |
OrapredODT | Human Prescription Drug Label | 1 | 59212-702 | TABLET, ORALLY DISINTEGRATING | 30 mg | ORAL | NDA | 25 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60432-212 | SOLUTION | 15 mg | ORAL | ANDA | 10 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-330 | SOLUTION | 5 mg | ORAL | ANDA | 16 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63187-215 | SOLUTION | 15 mg | ORAL | ANDA | 20 sections |
Prednisolone Sodium Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-667 | SOLUTION | 15 mg | ORAL | ANDA | 12 sections |
Prednisolone Sodium PhosphateODT | Human Prescription Drug Label | 1 | 66993-844 | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | NDA AUTHORIZED GENERIC | 25 sections |